title: Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer.
abstract: Microvessel density (MVD) has been associated with progression of prostate cancer. Although basic fibroblast growth factor (bFGF) is a known endothelial mitogen, the prognostic role of bFGF and its receptor FGFR-1 in prostate cancer has been controversial. The aim of our study was to examine the tissue distribution and prognostic significance of bFGF, FGFR-1, and microvascular proliferation. Sections from 104 radical prostatectomy specimens were examined by factor VIII/Ki-67 staining for proliferating capillary index (PCI) and MVD, and tissue microarray sections were immunostained for bFGF and FGFR-1. Increased PCI (median 0.49%) was related to strong stromal expression of bFGF (P=0.003) but was without prognostic impact. Strong bFGF staining was associated with well-differentiated tumors, no capsular penetration, low serum-prostate-specific antigen (s-PSA), low tumor cell proliferation, and increased time to biochemical failure (P=0.007), and was of independent prognostic importance in multivariate survival analysis. bFGF expression in vessels was associated with low MVD (P=0.0003). In contrast, strong tumor cell FGFR-1 expression was related to high preoperative s-PSA. Thus, increased stromal and vessel bFGF was associated with less aggressive tumors. Our findings indicate a complex relationship between bFGF/FGFR-1 expression and prognosis of prostate cancer. Vascular proliferation revealed no prognostic impact in this study.
authors.affiliation: Section for Pathology, The Gade Institute, Haukeland University Hospital, 5021 Bergen, Norway. Karsten.Gravdal@Haukeland.no
authors.forename: Karsten
authors.initials: K
authors.lastname: Gravdal
authors.forename: Ole J
authors.initials: OJ
authors.lastname: Halvorsen
authors.forename: Svein A
authors.initials: SA
authors.lastname: Haukaas
authors.forename: Lars A
authors.initials: LA
authors.lastname: Akslen
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D009389:Neovascularization, Pathologic / Q000378:metabolism*; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000098:blood supply / Q000378:metabolism* / Q000473:pathology; D040081:Protein Array Analysis; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000096:biosynthesis*; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D016222:Fibroblast Growth Factor 2; C496348:FGFR1 protein, human; D051496:Receptor, Fibroblast Growth Factor, Type 1